- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00749801
Efficacy and Safety of Geneferm Nattokinase
A Randomized, Double-Blind, Placebo-Controlled, Parallel Comparison Study to Evaluate the Efficacy and Safety of Oral Administration of Nattokinase (From GeneFerm Biotechnology Co., Ltd.) Taken by Dyslipidemia Patients
Study Overview
Detailed Description
This study will employ a randomized, double-blind, placebo-controlled, parallel-group design. Adult men and women who met the inclusion/exclusion criteria and gave consent to participate were randomly assigned to one of the three groups: Group A: nattokinase-mono formula (18 subjects); Group B: nattokinase compound (multiple formulae) (18 subjects); Group C: placebo (10 subjects).
Laboratory tests, including TG, total cholesterol, LDL-C, HDL-C, fibrinogen, D-Dimer, uric acid, vital signs and body weight will be evaluated at screening visit, 1 month, 3 months, 6 months visits after the initiation of treatment. Vital signs and body weight will be measured at every visits.
Patient self-evaluation of tolerance and physical improvement will be assessed by a Patient Questionnaire at each visit. Each patient will be carefully monitored for the development of any adverse events (AE).
The change of all lab tests and vital signs will be plotted and compared against time. Wilcoxon Signed-Rank test will be performed to compare the baseline and 6 months after the initiation of administration. Change from baseline for all lab and vital evaluations will be compared among three groups by Analysis of Variance (ANOVA) followed by LSD multiple comparison.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tainan, Taiwan, 710
- Chi Mei Medical Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and non-pregnant women above 40 years of age.
- Dyslipidemic currently being untreated with lipid-lowering drugs. Dyslipidemia is defined as: Total cholesterol 200~300 mg/dl; or Triglyceride 200~500 mg/dl; or Low density lipoprotein-cholesterol 130~200 mg/dl; or High density lipoprotein cholesterol <40 mg/dl (male) and <50 mg/dl (female).
- Subjects who are, in the opinion of the Investigator, able to comply with the requirements of the study.
- Subjects who have been adequately informed of the nature and risks of the study and who have given written informed consent prior to receiving investigational product.
Exclusion Criteria:
- Receipt of lipid-lowering drugs or device within 12 weeks.
- Myocardial infarction within the preceding 12 weeks.
- Recent major trauma (within 12 weeks).
- Recent surgery requiring anesthesia including coronary artery bypass graft (within 12 weeks).
- Recent hospitalization (within 12 weeks).
- Acute infection requiring current antibiotic therapy.
- Recent or abrupt change (within 1 month) in usual diet.
- Unstable medical condition or life expectancy less than 6 months.
- Known allergies to the component of study product.
- Patients have acute disease, and in the opinion of investigators, are not suitable to participate in this study.
- Total cholesterol >300 mg/dl; or Triglyceride >500 mg/dl; or Low density lipoprotein-cholesterol >200 mg/dl.
- Current use of warfarin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: C
Placebo
|
2 capsules in the morning and before bed-time daily
Other Names:
|
Active Comparator: A
nattokinase-mono formula (3500FU)
|
2 capsules in the morning and before bed-time daily
Other Names:
|
Experimental: B
Nattokinase compound-multiple formulae
|
2 capsules in the morning and before bed-time daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Fibrinogen, FDP (fibrin degradation product), D-dimer, Total cholesterol, LDL-C (Low-density lipoprotein cholesterol), HDL-C (High-density lipoprotein cholesterol), Triglyceride (TG), and Uric acid
Time Frame: screening, day 0, weeks 4, 13, 26
|
screening, day 0, weeks 4, 13, 26
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Vital signs and self-evaluated questionnaire
Time Frame: screening, day 0, weeks 4, 13, 26
|
screening, day 0, weeks 4, 13, 26
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Nae-Cherng Yang, PhD, Chung Chou Institute of Technology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Geneferm-N01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperlipidemia
-
Drug Commission of the German Medical AssociationMadaus AGTerminatedHypercholesterolemia | Combined Hyperlipidemia
-
Misr University for Science and TechnologyActive, not recruiting
-
DongKoo Bio & PharmaUnknownHyperlipidemia, HypertriglyceridemiaKorea, Republic of
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHypercholesterolemia and HyperlipidemiaChina
-
Jeil Pharmaceutical Co., Ltd.CompletedHypertension With HyperlipidemiaKorea, Republic of
-
PfizerWithdrawnPrimary Hyperlipidemia or Mixed DyslipidemiaChina
-
ShionogiIntegriumCompletedCombined HyperlipidemiaUnited States
-
IlDong Pharmaceutical Co LtdCompletedHypertension With HyperlipidemiaKorea, Republic of
-
HK inno.N CorporationCompletedHypertension With Hyperlipidemia
-
LG Life SciencesCompletedHypertension, HyperlipidemiaKorea, Republic of
Clinical Trials on Nattokinase
-
Universidade Federal FluminenseCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsNot yet recruitingEffects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With DyslipidemiaCardiovascular Diseases | Inflammation | Dyslipidemias
-
Second Affiliated Hospital, School of Medicine,...RecruitingCerebral Blood Flow | Cognitive FunctionChina
-
Changhua Christian HospitalCompleted
-
Natural Immune Systems IncJBSL-USA IncorporatedCompletedHypertension
-
University of Southern CaliforniaCompletedPrevention of Subclinical Atherosclerosis Progression | Prevention of Cognitive DeclineUnited States
-
Yonsei UniversityCompleted